|
Dec 27
|
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
|
|
Dec 27
|
Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls
|
|
Dec 20
|
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
|
|
Dec 8
|
Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy
|
|
Nov 27
|
How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%
|
|
Nov 16
|
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration
|
|
Nov 16
|
BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology
|
|
Nov 8
|
Fusion Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
Nov 7
|
Fusion Pharmaceuticals Inc (FUSN) Reports Q3 2023 Financial Results and Clinical Program Updates
|
|
Nov 7
|
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates
|
|
Nov 7
|
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
|
|
Aug 14
|
10 Oversold Penny Stocks To Buy
|
|
Aug 9
|
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 8
|
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 8
|
Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates
|